CN114100589A - Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine - Google Patents
Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine Download PDFInfo
- Publication number
- CN114100589A CN114100589A CN202110005257.6A CN202110005257A CN114100589A CN 114100589 A CN114100589 A CN 114100589A CN 202110005257 A CN202110005257 A CN 202110005257A CN 114100589 A CN114100589 A CN 114100589A
- Authority
- CN
- China
- Prior art keywords
- pva
- adsorbent
- acute
- resin
- cross
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003463 adsorbent Substances 0.000 title claims abstract description 49
- 239000011347 resin Substances 0.000 title claims abstract description 46
- 229920005989 resin Polymers 0.000 title claims abstract description 46
- 230000001154 acute effect Effects 0.000 title claims abstract description 23
- 230000008081 blood perfusion Effects 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims description 27
- 231100000570 acute poisoning Toxicity 0.000 title claims description 19
- 231100000739 chronic poisoning Toxicity 0.000 title claims description 19
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 70
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 70
- 238000004132 cross linking Methods 0.000 claims description 27
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- 238000003756 stirring Methods 0.000 claims description 23
- 230000007935 neutral effect Effects 0.000 claims description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 15
- 239000008213 purified water Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- 230000001951 hemoperfusion Effects 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- 238000006136 alcoholysis reaction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 239000002344 surface layer Substances 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 abstract description 5
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 239000012567 medical material Substances 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000001878 scanning electron micrograph Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003760 magnetic stirring Methods 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 208000005374 Poisoning Diseases 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/265—Synthetic macromolecular compounds modified or post-treated polymers
- B01J20/267—Cross-linked polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
The invention relates to the technical field of medical materials, and particularly discloses a method for modifying a blood perfusion resin adsorbent for acute and chronic drug poisoning.
Description
Technical Field
The invention relates to the field of medical materials, in particular to a method for modifying a blood perfusion resin adsorbent for acute and chronic poisoning of a medicine.
Background
Drug intoxication includes both acute and chronic types, including systemic diseases in which the drug enters the human body and accumulates to a certain extent at the site of effect to cause physical damage. The drug poisoning phenomenon comprises excessive intake poisoning of the sedative-hypnotic drugs such as pentobarbital, and is followed by drug anaphylaxis poisoning. The former chemical drugs such as pentobarbital are common in small molecules, while the latter drug anaphylaxis is usually caused by macromolecular substances. Although the phenomenon of drug anaphylaxis is rare but fatal, in general, macromolecular drugs such as protein, polysaccharide and polypeptide, such as serum, crude drug preparations, vaccines and the like, have complete antigenicity, can enable the body to generate corresponding antibodies, but are easy to sensitize the body. Meanwhile, poisoning of patients is usually accompanied by damage of kidney functions, which causes toxin accumulation of macromolecular substances such as beta 2-microglobulin and the like to cause a series of complications. With regard to poisoning, current clinical treatment and rescue measures include emetic and gastric lavage, and for patients with severe coma, blood purification is a more appropriate measure.
Clinically, as a novel blood purification technology, blood perfusion is applied to the treatment and rescue of patients suffering from acute and chronic poisoning of drugs. During the blood perfusion treatment process, the blood of a patient is directly treated with the adsorbent through extracorporeal circulation, certain endogenous or exogenous harmful substances are selectively adsorbed from the blood, the operation is simple, the cost is low, and the design requirement on the adsorbent is higher. At present, the commercially available resin adsorbent for hemoperfusion has good adsorption performance on toxic substances in blood, but has poor effect on removing macromolecular substances which can cause anaphylaxis.
Disclosure of Invention
In view of the above, the present invention aims to provide a method for modifying a hemoperfusion resin adsorbent for acute and chronic drug poisoning, wherein the obtained modified resin has good adsorption performance on substances causing acute and chronic drug poisoning in blood, and the modified resin adsorbent has good blood compatibility, high safety, economic and convenient preparation method, and can be widely applied in the field of medical materials.
In order to achieve the purpose, the invention adopts the following technical scheme:
a method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine comprises the following steps:
1) stirring purified water, adding a certain amount of PVA, continuously stirring to obtain a uniform PVA solution, heating to raise the temperature of the PVA solution to 80 ℃, and continuously keeping the temperature of 80 ℃ and stirring for 2-3 hours;
2) adding a cross-linking agent and a catalyst into the PVA aqueous solution obtained in the step 1) to carry out cross-linking reaction to obtain a PVA cross-linking solution;
3) adding neutral macroporous resin into the PVA cross-linking liquid prepared in the step 2), stirring to enable the PVA cross-linking liquid to be coated on the surface layer of the neutral macroporous resin to form a film, performing suction filtration to enable the residual PVA cross-linking liquid to be separated from the neutral macroporous resin to obtain the neutral macroporous resin with the PVA coated film as an adsorbent, then adding absolute ethyl alcohol into the adsorbent to fully disperse the adsorbent, washing with purified water until the pH value of the adsorbent is neutral, and finally obtaining the PVA film coated blood perfusion resin adsorbent for acute and chronic poisoning of the medicine.
Preferably, the PVA is medical grade polyvinyl alcohol, the alcoholysis degree is 88%, the polymerization degree is 500, 1700 and 2400 respectively, and the concentration of the PVA aqueous solution is 0.1-5%.
Preferably, the cross-linking agent is any one or any combination of formaldehyde, glutaraldehyde, oxalic acid, malonic acid and succinic acid.
Preferably, the catalyst is a 0.5mol/L sulfuric acid solution, and the volume ratio of the sulfuric acid solution to the PVA aqueous solution is 1: 50-1: 30.
preferably, the crosslinking reaction time is 20-60 min.
Preferably, the volume ratio of the PVA aqueous solution to the resin is 10: 1-5: 4.
preferably, the coating time is 5-10 min.
The invention has the beneficial effects that:
the blood perfusion modified resin adsorbent provided by the invention has excellent adsorption effect on substances causing acute and chronic poisoning of medicines and excellent blood purification effect; has good blood compatibility and high safety; the preparation method is economical, convenient and convenient, and convenient for application and production; the modified hemoperfusion resin adsorbent is used for adsorbing substances causing acute and chronic poisoning of medicines in blood and removing macromolecular toxin substances in the blood.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a scanning electron micrograph of an uncoated resin adsorbent.
FIG. 2 is a scanning electron micrograph of the coated resin adsorbent.
Detailed Description
The technical solution in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
1) Preparation of 2% PVA aqueous solution:
and (3) adding 490g of purified water weighed by an electronic balance into a 500ml beaker, carrying out magnetic stirring, weighing 10g of PVA, adding the PVA into the beaker, raising the temperature from 25 ℃ to 80 ℃ after uniform dispersion, and stirring for 3 hours to obtain a PVA aqueous solution fully dissolved.
2) Taking a 1000mL beaker, adding 400mL of prepared 2% PVA aqueous solution to the beaker at the normal temperature of 25 ℃, placing the beaker in a magnetic stirrer for stirring, then adding 2.09mL of formaldehyde by using a liquid transfer gun, and then dropwise adding 8.8 mL of 0.5mol/L sulfuric acid solution for crosslinking reaction for 1h to obtain PVA crosslinking solution;
3) 320 mL of neutral macroporous resin is measured by a measuring cylinder and added into the prepared PVA cross-linking liquid, stirring and coating are carried out for 5min, suction filtration is carried out to obtain a crude product adsorbent, then 1000mL of absolute ethyl alcohol is added to fully disperse the obtained adsorbent, purified water is used for washing to be neutral, and finally the blood perfusion resin adsorbent coated with the PVA film and used for acute and chronic poisoning of the medicine is obtained. The scanning electron micrograph of the modified resin adsorbent prepared in this example is shown in fig. 2.
Test method
An in vitro static adsorption experiment (a disposable hemoperfusion apparatus is used according to the standard YYT 0464-2019) is carried out, and the adsorption performance of the modified resin on sodium pentobarbital, vitamin B12 and cytochrome C is detected. The data obtained are shown in Table 1.
Example 2
1) Preparation of 2% PVA aqueous solution:
and (3) adding 490g of purified water weighed by an electronic balance into a 500ml beaker, carrying out magnetic stirring, weighing 10g of PVA, adding the PVA into the beaker, raising the temperature from 25 ℃ to 80 ℃ after uniform dispersion, and stirring for 3 hours to obtain a PVA aqueous solution fully dissolved.
2) Taking a 1000mL beaker, adding prepared 400mL of 2% PVA aqueous solution into the beaker, placing the beaker in a magnetic stirrer for stirring, then adding 2.74mL of glutaraldehyde by using a liquid transfer gun, and then dropwise adding 8.8 mL of 0.5mol/L sulfuric acid solution for carrying out crosslinking reaction for 1h to obtain PVA crosslinking solution;
3) 320 mL of neutral macroporous resin is measured by a measuring cylinder and added into the prepared PVA cross-linking liquid, stirring and coating are carried out for 5min, suction filtration is carried out to obtain a crude product adsorbent, then 1000mL of absolute ethyl alcohol is added to fully disperse the obtained adsorbent, purified water is used for washing to be neutral, and finally the blood perfusion resin adsorbent coated with the PVA film and used for acute and chronic poisoning of the medicine is obtained. The scanning electron micrograph of the modified resin adsorbent prepared in this example is shown in fig. 2. The test method was in accordance with example 1, and the data obtained are shown in Table 1.
Example 3
1) Preparation of 2% PVA aqueous solution:
and (3) adding 490g of purified water weighed by an electronic balance into a 500ml beaker, carrying out magnetic stirring, weighing 10g of PVA, adding the PVA into the beaker, raising the temperature from 25 ℃ to 80 ℃ after uniform dispersion, and stirring for 3 hours to obtain a PVA aqueous solution fully dissolved.
2) Taking a 1000mL beaker, adding 400mL of prepared 2% PVA aqueous solution into the beaker at the normal temperature of 25 ℃, placing the beaker in a magnetic stirrer for stirring, then weighing and adding 3.44g of oxalic acid by using an electronic balance, and then dropwise adding 8.8 mL of 0.5mol/L sulfuric acid solution for crosslinking reaction for 1h to obtain PVA crosslinking solution;
3) 320 mL of neutral macroporous resin is measured by a measuring cylinder and added into the prepared PVA cross-linking liquid, stirring and coating are carried out for 5min, suction filtration is carried out to obtain a crude product adsorbent, then 1000mL of absolute ethyl alcohol is added to fully disperse the obtained adsorbent, purified water is used for washing to be neutral, and finally the blood perfusion resin adsorbent coated with the PVA film and used for acute and chronic poisoning of the medicine is obtained. The scanning electron micrograph of the modified resin adsorbent prepared in this example is shown in fig. 2. The test method was in accordance with example 1, and the data obtained are shown in Table 1.
Example 4
1) Preparation of 2% PVA aqueous solution:
and (3) adding 490g of purified water weighed by an electronic balance into a 500ml beaker, carrying out magnetic stirring, weighing 10g of PVA, adding the PVA into the beaker, raising the temperature from 25 ℃ to 80 ℃ after uniform dispersion, and stirring for 3 hours to obtain a PVA aqueous solution fully dissolved.
2) Taking a 1000mL beaker, adding 400mL of prepared 2% PVA aqueous solution into the beaker at the normal temperature of 25 ℃, placing the beaker in a magnetic stirrer for stirring, then weighing and adding 2.84g of malonic acid by using an electronic balance, and then dropwise adding 8.8 mL of 0.5mol/L sulfuric acid solution for carrying out crosslinking reaction for 1h to obtain PVA crosslinking solution;
3) 320 mL of neutral macroporous resin is measured by a measuring cylinder and added into the prepared PVA cross-linking liquid, stirring and coating are carried out for 5min, suction filtration is carried out to obtain a crude product adsorbent, 1000mL of absolute ethyl alcohol is added to fully disperse the obtained adsorbent, purified water is used for washing to be neutral, and finally the PVA film-coated blood perfusion resin adsorbent for acute and chronic poisoning of the medicine is obtained. The scanning electron micrograph of the modified resin adsorbent prepared in this example is shown in fig. 2. The test method was in accordance with example 1, and the data obtained are shown in Table 1.
Example 5
1) Preparation of 2% PVA aqueous solution:
and (3) adding 490g of purified water weighed by an electronic balance into a 500ml beaker, carrying out magnetic stirring, weighing 10g of PVA, adding the PVA into the beaker, raising the temperature from 25 ℃ to 80 ℃ after uniform dispersion, and stirring for 3 hours to obtain a PVA aqueous solution fully dissolved.
2) Taking a 1000mL beaker, adding 400mL of prepared 2% PVA aqueous solution into the beaker at the normal temperature of 25 ℃, placing the beaker in a magnetic stirrer for stirring, then weighing and adding 3.22g of succinic acid by using an electronic balance, and then dropwise adding 8.8 mL of 0.5mol/L sulfuric acid solution for crosslinking reaction for 1h to obtain PVA crosslinking solution;
3) 320 mL of neutral macroporous resin is measured by a measuring cylinder and added into the prepared PVA cross-linking liquid, stirring and coating are carried out for 5min, suction filtration is carried out to obtain a crude product adsorbent, 1000mL of absolute ethyl alcohol is added to fully disperse the obtained adsorbent, purified water is used for washing to be neutral, and finally the PVA film-coated blood perfusion resin adsorbent for acute and chronic poisoning of the medicine is obtained. The scanning electron micrograph of the modified resin adsorbent prepared in this example is shown in fig. 2. The test method was in accordance with example 1, and the data obtained are shown in Table 1.
TABLE 1
It should be understood that the detailed description of the present invention is only for illustrating the present invention and is not limited by the technical solutions described in the embodiments of the present invention, and those skilled in the art should understand that the present invention can be modified or substituted equally to achieve the same technical effects; as long as the use requirements are met, the method is within the protection scope of the invention.
Claims (7)
1. A method for modifying a hemoperfusion resin adsorbent for acute and chronic poisoning of a medicine is characterized by comprising the following steps:
1) stirring purified water, adding a certain amount of PVA, continuously stirring to obtain a uniform PVA solution, heating to raise the temperature of the PVA solution to 80 ℃, and continuously keeping the temperature of 80 ℃ and stirring for 2-3 hours;
2) adding a cross-linking agent and a catalyst into the PVA aqueous solution obtained in the step 1) to carry out cross-linking reaction to obtain a PVA cross-linking solution;
3) adding neutral macroporous resin into the PVA cross-linking liquid prepared in the step 2), stirring to enable the PVA cross-linking liquid to be coated on the surface layer of the neutral macroporous resin to form a film, performing suction filtration to enable the residual PVA cross-linking liquid to be separated from the neutral macroporous resin to obtain the neutral macroporous resin with the PVA coated film as an adsorbent, then adding absolute ethyl alcohol into the adsorbent to fully disperse the adsorbent, washing with purified water until the pH value of the adsorbent is neutral, and finally obtaining the PVA film coated blood perfusion resin adsorbent for acute and chronic poisoning of the medicine.
2. The method as claimed in claim 1, wherein the PVA is medical grade polyvinyl alcohol, the alcoholysis degree is 88%, the polymerization degree is 500, 1700 and 2400 respectively, and the concentration of the aqueous solution of PVA is 0.1-5%.
3. The method for modifying a hemoperfusion resin adsorbent for acute and chronic poisoning by drugs according to claim 1, wherein the cross-linking agent is any one or any combination of formaldehyde, glutaraldehyde, oxalic acid, malonic acid and succinic acid.
4. The method as claimed in claim 1, wherein the catalyst is 0.5mol/L sulfuric acid solution, and the volume ratio of the sulfuric acid solution to the PVA aqueous solution is 1: 50-1: 30.
5. the method for modifying a hemoperfusion resin adsorbent for acute and chronic poisoning of a drug as claimed in claim 1, wherein the cross-linking reaction time is 20-60 min.
6. The method for modifying a hemoperfusion resin adsorbent for acute and chronic poisoning of a drug as claimed in claim 1, wherein the volume ratio of the PVA aqueous solution to the resin is 10: 1-5: 4.
7. the method for modifying a hemoperfusion resin adsorbent for acute and chronic poisoning of a drug as claimed in claim 1, wherein the coating time is 5-10 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110005257.6A CN114100589A (en) | 2021-01-05 | 2021-01-05 | Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110005257.6A CN114100589A (en) | 2021-01-05 | 2021-01-05 | Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114100589A true CN114100589A (en) | 2022-03-01 |
Family
ID=80359194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110005257.6A Pending CN114100589A (en) | 2021-01-05 | 2021-01-05 | Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114100589A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728432A (en) * | 1982-08-10 | 1988-03-01 | Japan Medical Supply Co., Ltd. | Method for decontaminating blood |
| CN2780207Y (en) * | 2005-04-12 | 2006-05-17 | 浙江科锐生物科技有限公司 | Disposable active carbon blood perfusion device |
| CN102671629A (en) * | 2011-03-15 | 2012-09-19 | 上海翠屹新材料科技有限公司 | Absorbent with high blood compatibility |
| CN105670021A (en) * | 2016-01-23 | 2016-06-15 | 武汉理工大学 | Method for wrapping semipermeable membrane on surface of solvent-impregnated resin |
| CN106268703A (en) * | 2015-11-04 | 2017-01-04 | 珠海健帆生物科技股份有限公司 | DNA immunization adsorbent and preparation method thereof |
| CN114106398A (en) * | 2021-01-04 | 2022-03-01 | 河南省驼人医疗科技有限公司 | Preparation method of macroporous resin |
-
2021
- 2021-01-05 CN CN202110005257.6A patent/CN114100589A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728432A (en) * | 1982-08-10 | 1988-03-01 | Japan Medical Supply Co., Ltd. | Method for decontaminating blood |
| CN2780207Y (en) * | 2005-04-12 | 2006-05-17 | 浙江科锐生物科技有限公司 | Disposable active carbon blood perfusion device |
| CN102671629A (en) * | 2011-03-15 | 2012-09-19 | 上海翠屹新材料科技有限公司 | Absorbent with high blood compatibility |
| CN106268703A (en) * | 2015-11-04 | 2017-01-04 | 珠海健帆生物科技股份有限公司 | DNA immunization adsorbent and preparation method thereof |
| CN105670021A (en) * | 2016-01-23 | 2016-06-15 | 武汉理工大学 | Method for wrapping semipermeable membrane on surface of solvent-impregnated resin |
| CN114106398A (en) * | 2021-01-04 | 2022-03-01 | 河南省驼人医疗科技有限公司 | Preparation method of macroporous resin |
Non-Patent Citations (1)
| Title |
|---|
| 陈长治,俞耀庭: "医用吸附剂及发展概况", 生物医学工程学杂志, no. 03, pages 213 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104959120B (en) | Inflammatory factor adsorbing agent for blood perfusion and preparation method | |
| CN110652891B (en) | Sulfydryl-containing modified blood purification membrane and preparation method thereof | |
| CN106238023B (en) | A kind of coating method for improving blood purification material surface biocompatibility | |
| CN114100589A (en) | Method for modifying blood perfusion resin adsorbent for acute and chronic poisoning of medicine | |
| CN115490867B (en) | Adsorption resin and preparation method and application thereof | |
| CN110975004A (en) | A liquid woundplast containing Notoginseng radix extract for rapidly forming film | |
| CN103301446B (en) | Affinity adsorption material for treating hyperbilirubinemia and preparation method thereof | |
| JP3087293B2 (en) | Sugar-responsive polymer complex | |
| CN112168776B (en) | Low-impurity high-stability torasemide injection and preparation method thereof | |
| JP2002517471A (en) | Method for producing carbonized resin DNA immunosorbent | |
| CN114209647A (en) | Hydroxyethyl starch injection and preparation method thereof | |
| FI93610C (en) | Object having a blood compatible surface layer and method for making articles having such a surface layer | |
| CN112876722A (en) | Traditional Chinese medicine coating for improving surface biocompatibility of medical instrument and preparation method thereof | |
| CN103462907A (en) | Omeprazole sodium freeze-dried powder injection for injection and preparation method thereof | |
| CN109608679B (en) | Preparation method of core-pore complex grafted polymer bionic membrane | |
| CN113018255B (en) | Preparation method of ferric carboxymaltose injection | |
| Altıntaş et al. | Affinity adsorption of recombinant human interferon‐α on monosize dye‐affinity beads | |
| CN117757108A (en) | Amphiphilic ionic polymer modified resin microsphere and preparation method and application thereof | |
| CN111529485B (en) | Preparation method of levetiracetam concentrated solution for injection | |
| JPH07816A (en) | Endotoxin adsorbent | |
| CN110841602B (en) | Blood purification material based on mussel bionic chemistry and preparation method thereof | |
| CN114149718B (en) | Film forming composition of biosensor and preparation method thereof | |
| CN113616643B (en) | Ornidazole preparation and preparation method and application thereof | |
| CN110123738B (en) | Polyacrylate hydrogel suppository for rectal delivery of puerarin and preparation method thereof | |
| CN114539310A (en) | Method for preparing high-purity phosphatidylethanolamine by adsorption method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220301 |
|
| RJ01 | Rejection of invention patent application after publication |